Fi­nal­ly, Cel­gene wins. Ane­mia drug lus­pa­ter­cept — part­nered with Ac­celeron — scores in PhI­II tri­al

Af­ter Cel­gene’s many trips and blun­ders this year, the phar­ma gi­ant might fi­nal­ly please in­vestors Thurs­day with cheery news from one of its late-stage block­buster hope­fuls. The com­pa­ny re­port­ed its ane­mia drug lus­pa­ter­cept has met pri­ma­ry and sec­ondary end­points in a Phase III tri­al.

Cel­gene $CELG, which is part­nered with Ac­celeron on the drug, said lus­pa­ter­cept “sig­nif­i­cant­ly” re­duced the need for blood trans­fu­sions in pa­tients with the blood dis­ease myelodys­plas­tic syn­drome (MDS).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.